Ghassan Abou-Alfa, MD (Liver Cancer)
Memorial Sloan-Kettering Cancer Center, New York, USA
Dr. Ghassan Abou-Alfa specializes in Hepatocellular Cancer as a Member of Memorial Sloan Kettering and Associate Professor of Medicine in Joan & Sanford I. Weill Medical College of Cornell University. He received his MD degree in American University of Beirut and served on the faculty of the Department of Medicine in Yale University School of Medicine before he joined Memorial Sloan Kettering Cancer Center and Joan & Sanford I. Weill Medical Scholl at Cornell University in 2001. Dr. Abou-Alfa also received his MBA from Columbia University in 2016.
Dr. Abou-Alfa’s research is dedicated to finding novel therapies and improving the effectiveness current therapies for hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer, while continuing to understand the basic mechanisms of the disease and its therapies. Dr Abou-Alfa has many publications in the field of hepatocellular carcinoma. He led on many occasions, international teams of investigators, and published the first report on the effective role of the novel agent sorafenib in the treatment of primary liver cancer and recently reported with colleagues from throughout the world, the positive outcome of the study he chaired on cabozantinib in the treatment of hepatocellular carcinoma in the New England Journal of Medicine. Dr. Abou-Alfa serves as the Chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers, and is the President-Elect for the International Society of Gastrointestinal Oncology. Dr Abou-Alfa chairs the hepatocellular carcinoma subgroup of the Alliance cooperative group, and is a cadre member of both the gastrointestinal cancers and pharmacogenomics and population pharmacology committees. Dr Abou-Alfa serves as the chair the medical/scientific board of the Cholangiocarcinoma Foundation and the Blue Faery Liver Foundation, and also serves on the National Medical Advisory Committee of the American Liver Foundation. Dr Abou-Alfa who has lectured worldwide on the subject on gastrointestinal malignancies, is also a strong advocate for raising awareness and support for improving the outcome of patients with these diseases, and enhancing oncologic education worldwide.